D68.3
Hemorrhagic disorder due to circulating anticoagulants
Clinical Classification Guidelines
Medical Intelligence & Overview
Hemorrhagic disorder due to circulating anticoagulants is a condition where abnormal substances in the blood interfere with normal clotting. This disorder can cause bleeding issues because the blood doesn't clot properly, leading to increased bleeding or bruising. It is classified under ICD-10 code D68.3 and is often linked to the presence of anticoagulant antibodies that disrupt the blood's ability to form clots effectively.
Causes & Symptoms
Clinical Causes: Presence of anticoagulant antibodies, such as lupus anticoagulant Use of certain medications affecting blood clotting, notably warfarin or heparin Underlying autoimmune disorders that generate circulating anticoagulants Clotting factor deficiencies that trigger antibody development against clotting factors Infections that can provoke immune responses leading to anticoagulant formation
Key Symptoms: Unexplained and prolonged bleeding or bruising Frequent nosebleeds (epistaxis) Heavy or irregular menstrual bleeding Bleeding gums or from minor cuts that take longer to stop Blood in urine (hematuria) Blood in stool (melena or hematochezia) Bleeding into joints or muscles, causing pain and swelling Possible development of blood clots despite bleeding tendencies
Diagnostic & Treatment
Diagnosis Path: Diagnosing hemorrhagic disorder due to circulating anticoagulants typically involves comprehensive blood tests, including: - Coagulation profiles such as PT (Prothrombin Time), aPTT (activated Partial Thromboplastin Time), and INR (International Normalized Ratio) - Specific tests for circulating anticoagulants, such as the lupus anticoagulant test - Assays to measure clotting factor levels and detect antibodies - Blood smear examinations and additional autoimmune workups Healthcare providers evaluate these results along with patient history to confirm the presence of circulating anticoagulants and rule out other bleeding disorders.
Treatment Protocols: Management of this disorder focuses on controlling bleeding episodes and addressing the underlying cause: - Use of blood products like fresh frozen plasma or clotting factor concentrates during active bleeding - Immunosuppressive therapies, such as corticosteroids, to reduce antibody production - Avoidance of medications that exacerbate bleeding, including certain anticoagulants - Careful monitoring of blood clotting levels and symptoms - In some cases, intravenous immunoglobulin (IVIG) therapy may be used to diminish antibody effects Consultation with hematology specialists is crucial for tailored treatment plans based on individual patient needs.
Clinical Advice & FAQs
Billing Guidance
Is D68.3 a billable ICD-10 code?
Yes, D68.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D68.3?
Clinical documentation must specify the nature of Hemorrhagic disorder due to circulating anticoagulants and any associated comorbidities for accurate reporting.
Cite this Clinical Reference